Posted 5th September 2018 by Jane Williams
I don’t need to tell you that pharma has changed, that it is still changing at speed, or that change is the new normal. I don’t need to tell you because you − more than anyone else − already know. The passing of the blockbuster era has caused uncertainty. Without the superstar drugs of old, where does the industry go next? It’s a serious challenge, but without challenge, there is no change. The answer, of course, is the scalar shift from blockbuster generic to precision medicine specific.
Posted 3rd September 2018 by Jane Williams
Brandon Allgood is the Chief Technology Officer at Numerate, as well as a co-founder. In addition to being responsible for the development of Numerate’s cloud-based machine learning platforms, Brandon runs the software & data science teams, and is the technical lead on all of the companies internal drug programs, as well as external collaborations.
Here, Brandon talks about what he thinks the future holds for AI and machine learning:
Posted 24th August 2018 by Jane Williams
We spoke to Alex Bastian about how he got started in precision medicine, where he sees it going and how he intends to use real world evidence to unlock the potential around personalised approaches to drug development:
Posted 20th April 2018 by Jane Williams
With genetic data making headlines, Aris Baras reflects on how genetic research can further advancements in medicine and delves into how his team’s work on large-scale approach is paving the way for new discoveries and enhanced patient care.
Posted 24th November 2017 by Jane Williams
Therapeutic interventions have traditionally been developed for patients with established pathologies and overt clinical symptoms. Many diseases however, are not tractable in later stages and therefore therapies are needed that intervene earlier in the disease continuum.
Posted 15th November 2017 by Jane Williams
Cancer poses a formidable challenge to public health in modern society. In duelling rituals, the challenged party is usually given the choice of weapons, and possibilities are numerous. Knowing the weaknesses of your opponent is key to combat strategies and weapon selection.
Posted 8th November 2017 by Jane Williams
The quest for magic bullets started with Paul Ehrlich. He wanted to target the syphilis bacteria without harming the patients, which led to Salvarsan. Ehrlich was a foundational thinker, and we owe him modern concepts such as receptor and pharmacophore. His impact on the field – seeking the ideal molecules – pervades drug discovery.